Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 17 of 65 · 3101 articles
This study compares bloodstream infection risk across commonly used biologics for IBD, which could affect decisions about choosing or monitoring biologic therapy. It also highlights that steroid co-use may increase...
Dietary approaches that reduce gut inflammation could offer a low‑risk option to help manage symptoms and biomarkers in Crohn’s disease. This trial specifically tests a catered anti‑inflammatory diet and measures fecal...
Hospitalized patients with acute severe ulcerative colitis face high risks of colectomy and steroid-related harms. This trial tests whether an oral JAK1 inhibitor (upadacitinib) started in hospital can avoid steroids,...
This post‑marketing study will add safety and real‑world effectiveness information about Tabellvi® (adalimumab) in Chinese adults with moderate to severe Crohn's disease, which can inform patients and clinicians using or...
Real-world registries can show how a drug performs outside clinical trials and how patients feel over time; this study aimed to track symptoms for people starting mirikizumab for ulcerative colitis.
If true, prenatal and early-life exposures could influence long-term IBD risk by shaping immune development and the gut microbiome, which may help explain why some people develop IBD and others don’t.
Diet is a modifiable factor many people with IBD try to use to manage symptoms and disease; this review summarizes what is and isn’t supported by current evidence for popular diets and structured nutritional therapies.
The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and AI and data science. The original article is from Toxicological Research.
Based on the title and source metadata, this appears to be an opinion or commentary related to Inflammatory bowel disease and Research and clinical trials. The original article is from Expert opinion on emerging drugs.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
High first-use usability suggests MyTARGET could be acceptable to many adults with IBD and that targeted refinements (error handling, demonstrating time savings) might improve uptake and recommendation.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from The Turkish journal of...
A bibliometric map of perianal fistula research helps patients and clinicians see how much work exists, which centers and authors lead the field, and which topics cluster together—useful when looking for expertise or...
Noninvasive fecal biomarkers are widely used to track IBD activity. Knowing whether different FC assays give comparable results and whether combining tests adds value affects how patients and clinicians interpret...
Cure8 could only read part of this source from INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, so this card uses cautious topic tags instead of a full summary. It is tagged...
Malnutrition is common but under-recognized in ulcerative colitis; a simple, more sensitive screening tool could help clinicians find patients who need nutritional assessment and support earlier.
The study suggests ulcerative colitis shows greater mucosal immune variability across sex, age and severity than Crohn’s disease, which could affect how patients are grouped for research or future personalized...
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Scientific Reports.
This identifies a metabolism-related epithelial gene (PCK1) linked to inflammation in UC and suggests acetyl‑L‑carnitine can partially reverse those changes in cell and mouse models—information that could guide future...
If you have UC, bowel urgency may indicate active inflammation more reliably than some other symptoms. Recognizing urgency could help prompt timely objective testing and treatment decisions.
This pooled analysis compares serious-infection and sepsis risks across advanced therapies used in immune-mediated inflammatory diseases, including IBD. It suggests JAK inhibitors are linked to higher serious-infection...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Guselkumab. The original article is from Clinical gastroenterology and hepatology...
Perianal fistulising Crohn's disease is hard to treat and often fails anti-TNF drugs. This study will provide real-world data on whether upadacitinib can be effective and safe for patients with refractory perianal...
This study compares two commonly used biologics as first-line therapy for moderate-to-severe ulcerative colitis and reports better short- and long-term effectiveness for vedolizumab with similar safety. The results could...
Researchers used clustering on mixed clinical and treatment data to identify distinct Crohn's disease course trajectories and a small high-burden subgroup. If validated, such trajectories might help inform prognosis and...
Links between circulating adaptive receptors, coordinated immune programs, and short-term treatment-response signals could eventually enable blood-based immune biomarkers or patient stratification tools in IBD research...
Genetic testing can help identify both rare high-impact variants and a person’s polygenic risk, which may affect screening discussions and family risk awareness. For people with a family history or ancestry-related risk,...
The study suggests stromal fibroblasts can drive pro-inflammatory neutrophil programs in ulcerative colitis and that targeting fibroblast-associated pathways may reduce neutrophil-driven inflammation—information that...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Ulcerative colitis, and Crohn's disease.
A colon-targeted, enzyme-activated imaging probe could help distinguish early versus late inflammatory stages in IBD and provide a noninvasive fecal fluorescence signal—potentially improving disease monitoring beyond...
The review highlights marine polysaccharides as multi-target agents that could modulate inflammation, the microbiome, and the gut barrier—processes central to ulcerative colitis—and points to possible roles as functional...
Cure8 found this source from app.dealroom.co, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
The study identifies a food-industry by-product (crayfish shells) as a source of peptides that reduced inflammation and improved barrier and antioxidant markers in cell and mouse colitis models—research that could inform...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, AI and data science, and Research and clinical trials. The original article is from BMC Medical Research...
Real-world registry data on upadacitinib can help patients and clinicians understand how the drug performs outside clinical trials, including patterns of use, effectiveness, and safety over time.
Identifies a fibroblast senescence signature and highlights ADAMTS2 as a candidate biomarker linked to inflammation and fibrosis in IBD, which could guide future diagnostic or therapeutic research relevant to Crohn’s...
A simple blood lymphocyte percentage could be a convenient, non-invasive marker to help distinguish endoscopic remission from active disease in both Crohn’s and ulcerative colitis; chemokines CXCL10 and CCL25 may also...
The report explores NOD2/CARD15 variants in a Djiboutian IBD cohort and suggests higher variant frequencies in Crohn’s disease, which could point to population-specific genetic susceptibility. It also raises khat use as...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Research and clinical trials. The original article is from Indian Journal of...
Cure8 found this source from bioengineer.org, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
The paper links specific gut bacteria, inflammatory cytokines, and two microRNAs with UC activity, which could point toward new diagnostic biomarkers or targets for research into disease mechanisms.
Dietary macronutrients affect microbiota, barrier integrity, and mucosal immunity in ways that could alter IBD activity. Understanding these pathways could inform more targeted dietary strategies beyond generic...
Extracellular vesicle (EV) therapies are being explored as new ways to modulate immune responses and promote mucosal repair in IBD, which could eventually expand treatment options beyond current biologics and small...
Persistent diarrhea is a common, quality-of-life–limiting problem in ulcerative colitis; this review synthesizes how epithelial transport, barrier damage, immune signaling, mitochondria, and microbiota interact and...
People with IBD or their clinicians may worry that systemic antifungal treatment could trigger flares.
Non-invasive imaging biomarkers that track intestinal inflammation and structure could speed preclinical testing of IBD therapies and guide translational imaging research relevant to clinical monitoring of ulcerative...
This study compares two JAK inhibitors (upadacitinib and tofacitinib) used as rescue therapy for acute severe ulcerative colitis and reports lower 1‑year colectomy rates with upadacitinib. That could influence choices...
